High Expression of Ubiquitin C-terminal Hydrolase L1 Is Associated With Poor Prognosis in Endometrial Cancer Patients

被引:8
作者
Nakao, Kohshiro [1 ]
Hirakawa, Takashi [1 ]
Suwa, Hiroto [1 ]
Kogure, Kayoko [1 ]
Ikeda, Sadatomo [1 ]
Yamashita, Soichi [1 ]
Minegishi, Takashi [1 ]
Kishi, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Obstet & Gynecol, Maebashi, Gunma 3718511, Japan
关键词
Endometrial cancer; Metastasis; Prognostic factor; UCHL1; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; INTERMEDIATE-RISK; PROTEASOME INHIBITOR; L1CAM EXPRESSION; RANDOMIZED-TRIAL; CARCINOMA; RADIOTHERAPY; PGP9.5; CELLS;
D O I
10.1097/IGC.0000000000001201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The ubiquitin C-terminal hydrolase L1 (UCHL1) plays a key role in tumor invasion and metastasis. Ubiquitin C-terminal hydrolase L1 is overexpressed in various cancers and reported to be correlated with a poor prognosis. The objective of this study was to determine the prognostic significance of UCHL1 in endometrial cancer. Methods The expression of UCHL1 in endometrial cancer was assessed using quantitative reverse transcription polymerase chain reaction and immunohistochemistry in 56 and 215 resected tumor specimens, respectively. Results The 4-year survival rates of the high UCHL1 messenger RNA expression group and high UCHL1 protein expression group were 78% and 71%, respectively, compared with 96% and 95% for the low UCHL1 messenger RNA expression group and low UCHL1 protein expression group, respectively. Kaplan-Meier and log-rank tests indicated a significant correlation between expression of UCHL1 and disease-free survival and overall survival. Moreover, multivariate stepwise Cox proportional hazard regression model analysis showed that UCHL1 was a significant independent marker for predicting a poor disease-free survival and overall survival. In 43 patients with metastatic lesions, immunohistochemical analysis of metastatic lesions revealed that the recurrence rate and mortality rate were 62% and 41%, respectively, in 29 UCHL1-positive patients and 36% and 29%, respectively, in 14 UCHL1-negative patients. Conclusions The results of this study suggest that high UCHL1 expression is a strong marker of poor prognosis of endometrial cancer. Furthermore, we suggest that UCHL1 may be involved in the development of distant metastasis in endometrial cancer.
引用
收藏
页码:675 / 683
页数:9
相关论文
共 41 条
  • [1] 2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA
    BOKHMAN, JV
    [J]. GYNECOLOGIC ONCOLOGY, 1983, 15 (01) : 10 - 17
  • [2] Development of the proteasome inhibitor Velcade™ (Bortezomib) by Julian!Adams, Ph.D., and Michael!Kauffman, MD, Ph.D.
    Bold, R
    [J]. CANCER INVESTIGATION, 2004, 22 (02) : 328 - 329
  • [3] Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
    Coughlin, Kathleen
    Anchoori, Ravi
    Iizuka, Yoshie
    Meints, Joyce
    MacNeill, Lauren
    Vogel, Rachel Isaksson
    Orlowski, Robert Z.
    Lee, Michael K.
    Roden, Richard B. S.
    Bazzaro, Martina
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3174 - 3186
  • [4] Carcinoma of the corpus uteri
    Creasman, W. T.
    Odicino, F.
    Maisonneuve, P.
    Quinn, M. A.
    Beller, U.
    Benedet, J. L.
    Heintz, A. P. M.
    Ngan, H. Y. S.
    Pecorelli, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 : S105 - S143
  • [5] Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:: multicentre randomised trial
    Creutzberg, CL
    van Putten, WLJ
    Koper, PCM
    Lybeert, MLM
    Jobsen, JJ
    Wárlám-Rodenhuis, CC
    De Winter, KAJ
    Lutgens, LCHW
    van den Bergh, ACM
    van de Steen-Banasik, E
    Beerman, H
    van Lent, M
    [J]. LANCET, 2000, 355 (9213) : 1404 - 1411
  • [6] Protein gene product 9.5 and ubiquitin are expressed in metabolically active epithelial cells of normal and pathologic human kidney
    Diomedi-Camassei, F
    Ravà, L
    Lerut, E
    Callea, F
    Van Damme, B
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (12) : 2714 - 2719
  • [7] Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer
    Dobrzycka, Bozena
    Terlikowski, Slawomir J.
    Mazurek, Andrzej
    Kowalczuk, Oksana
    Niklinska, Wieslawa
    Chyczewski, Lech
    Kulikowski, Marek
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (03) : 612 - 621
  • [8] USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
    Eichhorn, Pieter J. A.
    Rodon, Laura
    Gonzalez-Junca, Alba
    Dirac, Annette
    Gili, Maguei
    Martinez-Saez, Elena
    Aura, Claudia
    Barba, Ignasi
    Peg, Vicente
    Prat, Aleix
    Cuartas, Isabel
    Jimenez, Jose
    Garcia-Dorado, David
    Sahuquillo, Juan
    Bernards, Rene
    Baselga, Jose
    Seoane, Joan
    [J]. NATURE MEDICINE, 2012, 18 (03) : 429 - U192
  • [9] Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus
    Ervine, Aaron
    Leung, Sam
    Gilks, C. Blake
    McCluggage, W. Glenn
    [J]. HISTOPATHOLOGY, 2014, 64 (06) : 840 - 846
  • [10] UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α
    Goto, Yoko
    Zeng, Lihua
    Yeom, Chan Joo
    Zhu, Yuxi
    Morinibu, Akiyo
    Shinomiya, Kazumi
    Kobayashi, Minoru
    Hirota, Kiichi
    Itasaka, Satoshi
    Yoshimura, Michio
    Tanimoto, Keiji
    Torii, Masae
    Sowa, Terumasa
    Menju, Toshi
    Sonobe, Makoto
    Kakeya, Hideaki
    Toi, Masakazu
    Date, Hiroshi
    Hammond, Ester M.
    Hiraoka, Masahiro
    Harada, Hiroshi
    [J]. NATURE COMMUNICATIONS, 2015, 6